These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 30146960

  • 21. Innovation of novel antibiotics: an economic perspective.
    McKellar MR, Fendrick AM.
    Clin Infect Dis; 2014 Oct 15; 59 Suppl 3():S104-7. PubMed ID: 25261536
    [Abstract] [Full Text] [Related]

  • 22. Hospital pricing policies: the simple economics.
    Robison GA, Robison HD.
    Health Care Strateg Manage; 1986 Oct 15; 4(10):21-5. PubMed ID: 10311825
    [Abstract] [Full Text] [Related]

  • 23. Cost-effectiveness and pricing of antibacterial drugs.
    Verhoef TI, Morris S.
    Chem Biol Drug Des; 2015 Jan 15; 85(1):4-13. PubMed ID: 25521641
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Outpatient parenteral antibiotic therapy. Management of serious infections. Part I: Medical, socioeconomic, and legal issues. Reimbursement.
    Tierce JC.
    Hosp Pract (Off Ed); 1993 Jun 15; 28 Suppl 1():44-51. PubMed ID: 8505398
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. What are the economic barriers of antibiotic R&D and how can we overcome them?
    Renwick M, Mossialos E.
    Expert Opin Drug Discov; 2018 Oct 15; 13(10):889-892. PubMed ID: 30175625
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Novel approaches are needed to develop tomorrow's antibacterial therapies.
    Spellberg B, Bartlett J, Wunderink R, Gilbert DN.
    Am J Respir Crit Care Med; 2015 Jan 15; 191(2):135-40. PubMed ID: 25590154
    [Abstract] [Full Text] [Related]

  • 33. Coronary stents and the uptake of new medical devices in the German system of inpatient reimbursement.
    Henschke C, Baeumler M, Gaskins M, Busse R.
    J Interv Cardiol; 2010 Dec 15; 23(6):546-53. PubMed ID: 20735711
    [Abstract] [Full Text] [Related]

  • 34. An antibiotic's journey from marketing authorization to use, Norway.
    Årdal C, Blix HS, Plahte J, Røttingen JA.
    Bull World Health Organ; 2017 Mar 01; 95(3):220-226. PubMed ID: 28250535
    [Abstract] [Full Text] [Related]

  • 35. Reform of prescription drug reimbursement and pricing in the German social health insurance market: a comparison of three scenarios.
    Gress S, Niebuhr D, May U, Wasem J.
    Pharmacoeconomics; 2007 Mar 01; 25(6):443-54. PubMed ID: 17523750
    [Abstract] [Full Text] [Related]

  • 36. Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations.
    Persson U, Norlin JM.
    Appl Health Econ Health Policy; 2018 Apr 01; 16(2):157-165. PubMed ID: 29470774
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Implementation of a Market Entry Reward within the United States.
    Daniel GW, Schneider M, Lopez MH, McClellan MB.
    J Law Med Ethics; 2018 Jun 01; 46(1_suppl):50-58. PubMed ID: 30146957
    [Abstract] [Full Text] [Related]

  • 40. Resistance to antibiotics: are we in the post-antibiotic era?
    Alanis AJ.
    Arch Med Res; 2005 Jun 01; 36(6):697-705. PubMed ID: 16216651
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.